You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The test will be used in the trial to improve understanding of molecular resistance mechanisms to Pfizer's Lorviqua and other ALK inhibitors.
The company is studying TAS0953/HM06 in roughly 200 patients in Japan and the US whose tumors harbor RET gene abnormalities.
After the CANTATA trial failed, the company said it will reduce its workforce and direct resources to advancing the drug in KEAP1/NRF2-mutated NSCLC.
Sema4 will use its next-generation sequencing testing services to identify patients with solid tumors harboring NRG1 fusions for Merus' Phase I/II drug trial.
The study is evaluating the drug in previously treated NSCLC patients with alterations in EGFR, ALK, ROS1, NTRK, BRAF, MET, or RET.
The FDA has issued a clinical hold on the company's Phase I/II clinical trial of BPX-601 in patients with advanced pancreatic, gastric, and prostate cancer.
The study, slated to begin in the first half of 2021, follows recent discussion with the FDA and promising Phase II data presented at the ASH annual meeting.
Researchers presented data exploring CLL patients' outcomes on fixed-duration combination regimens and on using uMRD to decide which patients can stop treatment.
The FDA has accepted the firm's IND application allowing it to start a dose escalation and expansion study of the drug in the first quarter of 2021.
Kymriah and Yescarta were evaluated in indolent NHL subtypes, and Yescarta was evaluated in the front-line setting for high-risk large B-cell lymphoma.